125 related articles for article (PubMed ID: 17428162)
1. Paclitaxel poliglumex (PPX, CT-2103): macromolecular medicine for advanced non-small-cell lung cancer.
Bonomi P
Expert Rev Anticancer Ther; 2007 Apr; 7(4):415-22. PubMed ID: 17428162
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel poliglumex (XYOTAX, CT-2103): a macromolecular taxane.
Singer JW
J Control Release; 2005 Dec; 109(1-3):120-6. PubMed ID: 16297482
[TBL] [Abstract][Full Text] [Related]
3. Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer.
Paz-Ares L; Ross H; O'Brien M; Riviere A; Gatzemeier U; Von Pawel J; Kaukel E; Freitag L; Digel W; Bischoff H; García-Campelo R; Iannotti N; Reiterer P; Bover I; Prendiville J; Eisenfeld AJ; Oldham FB; Bandstra B; Singer JW; Bonomi P
Br J Cancer; 2008 May; 98(10):1608-13. PubMed ID: 18475293
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies.
Mita M; Mita A; Sarantopoulos J; Takimoto CH; Rowinsky EK; Romero O; Angiuli P; Allievi C; Eisenfeld A; Verschraegen CF
Cancer Chemother Pharmacol; 2009 Jul; 64(2):287-95. PubMed ID: 19034451
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer.
O'Brien ME; Socinski MA; Popovich AY; Bondarenko IN; Tomova A; Bilynsky BT; Hotko YS; Ganul VL; Kostinsky IY; Eisenfeld AJ; Sandalic L; Oldham FB; Bandstra B; Sandler AB; Singer JW
J Thorac Oncol; 2008 Jul; 3(7):728-34. PubMed ID: 18594318
[TBL] [Abstract][Full Text] [Related]
6. Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate.
Li C; Yu DF; Newman RA; Cabral F; Stephens LC; Hunter N; Milas L; Wallace S
Cancer Res; 1998 Jun; 58(11):2404-9. PubMed ID: 9622081
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo metabolism of paclitaxel poliglumex: identification of metabolites and active proteases.
Shaffer SA; Baker-Lee C; Kennedy J; Lai MS; de Vries P; Buhler K; Singer JW
Cancer Chemother Pharmacol; 2007 Mar; 59(4):537-48. PubMed ID: 16924498
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane.
Singer JW; Shaffer S; Baker B; Bernareggi A; Stromatt S; Nienstedt D; Besman M
Anticancer Drugs; 2005 Mar; 16(3):243-54. PubMed ID: 15711176
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of hydrophilic Paclitaxel copolymer prodrug using locoregional delivery in human orthotopic non-small cell lung cancer xenograft models.
Zou Y; Fu H; Ghosh S; Farquhar D; Klostergaard J
Clin Cancer Res; 2004 Nov; 10(21):7382-91. PubMed ID: 15534115
[TBL] [Abstract][Full Text] [Related]
10. CT-2103 extends median survival of high-risk lung cancer patients.
Oncology (Williston Park); 2003 Dec; 17(12):1804, 1809. PubMed ID: 14723015
[No Abstract] [Full Text] [Related]
11. Paclitaxel poliglumex. Cell Therapeutics/Chugai Pharmaceutical.
Man M; Rugo H
IDrugs; 2005 Sep; 8(9):739-54. PubMed ID: 16118697
[TBL] [Abstract][Full Text] [Related]
12. A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules.
Boddy AV; Plummer ER; Todd R; Sludden J; Griffin M; Robson L; Cassidy J; Bissett D; Bernareggi A; Verrill MW; Calvert AH
Clin Cancer Res; 2005 Nov; 11(21):7834-40. PubMed ID: 16278406
[TBL] [Abstract][Full Text] [Related]
13. CT-2103: a novel macromolecular taxane with potential advantages compared with conventional taxanes.
Langer CJ
Clin Lung Cancer; 2004 Dec; 6 Suppl 2():S85-8. PubMed ID: 15638965
[TBL] [Abstract][Full Text] [Related]
14. A phase I and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors.
Verschraegen CF; Skubitz K; Daud A; Kudelka AP; Rabinowitz I; Allievi C; Eisenfeld A; Singer JW; Oldham FB
Cancer Chemother Pharmacol; 2009 Apr; 63(5):903-10. PubMed ID: 18682950
[TBL] [Abstract][Full Text] [Related]
15. Phase II clinical trial of XYOTAX in non-small cell lung cancer to continue.
Expert Rev Anticancer Ther; 2002 Jun; 2(3):244-5. PubMed ID: 12113042
[No Abstract] [Full Text] [Related]
16. Biological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer-drug conjugate.
Chipman SD; Oldham FB; Pezzoni G; Singer JW
Int J Nanomedicine; 2006; 1(4):375-83. PubMed ID: 17722272
[TBL] [Abstract][Full Text] [Related]
17. Effect of molecular weight of PGG-paclitaxel conjugates on in vitro and in vivo efficacy.
Yang D; Liu X; Jiang X; Liu Y; Ying W; Wang H; Bai H; Taylor WD; Wang Y; Clamme JP; Co E; Chivukula P; Tsang KY; Jin Y; Yu L
J Control Release; 2012 Jul; 161(1):124-31. PubMed ID: 22521595
[TBL] [Abstract][Full Text] [Related]
18. PIONEER: a phase III randomized trial of paclitaxel poliglumex versus paclitaxel in chemotherapy-naive women with advanced-stage non-small-cell lung cancer and performance status of 2.
Albain KS; Belani CP; Bonomi P; O'Byrne KJ; Schiller JH; Socinski M
Clin Lung Cancer; 2006 May; 7(6):417-9. PubMed ID: 16800969
[No Abstract] [Full Text] [Related]
19. Prevention of local tumor recurrence following surgery using low-dose chemotherapeutic polymer films.
Liu R; Wolinsky JB; Walpole J; Southard E; Chirieac LR; Grinstaff MW; Colson YL
Ann Surg Oncol; 2010 Apr; 17(4):1203-13. PubMed ID: 19957041
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel poliglumex for ovarian cancer.
Galic VL; Wright JD; Lewin SN; Herzog TJ
Expert Opin Investig Drugs; 2011 Jun; 20(6):813-21. PubMed ID: 21470062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
